Guest Column | November 25, 2020

What The Gene Therapy Sector Doesn't Understand About CRISPR


By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1

DNA Strand

I sat down with Sadik Kassim, Chief Technical Officer at Vor Biopharma to discuss the benefits of CRISPR-engineered stem cell therapies, the challenges and feasible solutions, what’s next, and more.

What You’re Probably Thinking

It’s smart to temper the hype of the actual data. Like any medicine or tool, you must figure out the biology and determine if CRISPR-edited stem cells or other cell types are the right tool.

The Truth of the Matter

CRISPR-edited stem cells can be applied across a broad category of diseases. There will be more limited application depending on the disease itself.